Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meridian to acquire recombinant proteins from Vybion
The purchase price includes cash and future royalties based on net sales of the acquired products, the amounts of which were not disclosed. The assets to be acquired
The purchase price includes cash and future royalties based on net sales of the acquired products, the amounts of which were not disclosed. The assets to be acquired
These devices represent entirely new platforms to treat heart failure and sudden cardiac death and are the result of a multi-year R&D effort to provide physicians enhanced clinical
The company expects to grant a 30-day option to the underwriters to purchase up to an additional 15% of the shares offered solely to cover over-allotments. All of
Through the acquisition, BD (Becton, Dickinson and Company) gains the scientific leadership and insights of Ger van den Engh, a renowned innovator in flow cytometry. Dr van den
Mr Stanley Wong has resigned as president and CEO of the company, effective as of June 1, 2008. Mr Wong’s resignation was due to personal reasons and was
The trial is designed to assess the safety, tolerability and pharmacokinetics of CCX354 in healthy volunteers in single ascending dose and multiple ascending dose cohorts. Preclinical studies showed
There are three segments to the pivotal trial design. During the first segment of the trial, five non-randomized patients will be treated with Sepet to validate the patient
In his new role, Giancola will lead the global organization to gain further market acceptance and continue the growth of Neuromonics. Prior to joining Neuromonics, Giancola was a
The revised Association of the British Pharmaceutical Industry Code of Practice (ABPI Code), which comes into force from July 1, 2008 includes specific requirements for companies on informing
HPV 16 E7-specific T-cell responses were elicited in all four subjects in the study’s third cohort following administration of 500mcg of HspE7 and 1,000mcg of Poly-ICLC, a potent